These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
295 related items for PubMed ID: 21851507
1. Risk of inhibitor development in mild haemophilia A increases with age. Mauser-Bunschoten EP, Den Uijl IE, Schutgens RE, Roosendaal G, Fischer K. Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507 [Abstract] [Full Text] [Related]
3. Treatment related factors and inhibitor development in children with severe haemophilia A. Maclean PS, Richards M, Williams M, Collins P, Liesner R, Keeling DM, Yee T, Will AM, Young D, Chalmers EA, Paediatric Working Party of UKHCDO. Haemophilia; 2011 Mar; 17(2):282-7. PubMed ID: 21070501 [Abstract] [Full Text] [Related]
7. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010. Vézina C, Carcao M, Infante-Rivard C, Lillicrap D, Stain AM, Paradis E, Teitel J, Rivard GE, Association of Hemophilia Clinic Directors of Canada and of the Canadian Association of Nurses in Hemophilia Care. Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669 [Abstract] [Full Text] [Related]
8. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A. Franchini M, Girelli D, Olivieri O, Castaman G, Lippi G, Poli G, Salvagno GL, Tagariello G, Giuffrida A, de Gironcoli M, Morfini M, Berntorp E, Gandini G. Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751 [Abstract] [Full Text] [Related]
9. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. Haemophilia; 2010 Mar; 16(2):256-62. PubMed ID: 19878331 [Abstract] [Full Text] [Related]
17. Thirteen novel mutations in the factor VIII gene in the Nijmegen haemophilia A patient population. Boekhorst J, Verbruggen B, Lavergne JM, Costa JM, Schoormans SC, Brons PP, van Kraaij MG, Nováková IR, van Heerde WL. Br J Haematol; 2005 Oct; 131(1):109-17. PubMed ID: 16173970 [Abstract] [Full Text] [Related]
19. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM, RITS-FITNHES Study Group. Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550 [Abstract] [Full Text] [Related]
20. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W, Hemophilia Inhibitor Research Study Investigators. Haemophilia; 2012 May; 18(3):375-82. PubMed ID: 22103590 [Abstract] [Full Text] [Related] Page: [Next] [New Search]